• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BioAge Labs Inc.

    11/14/24 4:15:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    SC 13G 1 d871469dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    BioAge Labs, Inc.

    (Name of Issuer)

    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

    09077V100

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No: 09077V100  

     

     1   

     NAMES OF REPORTING PERSONS

     

     Khosla Ventures VI, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     437,152 (2)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     437,152 (2)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     437,152 (2)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     1.2% (3)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This statement on Schedule 13G is filed by Khosla Ventures VI, LP (“KV VI”), Khosla Ventures Opportunity I, LP (“KV Opp I”), Khosla Ventures Associates VI, LLC (“KVA VI”), Khosla Ventures Opportunity Associates I, LLC (“KVOA I”), VK Services, LLC (“VK Services”) and Vinod Khosla (“Khosla,” together with KV VI, KV Opp I, KVA VI, KVOA I and VK Services collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    All of the shares are owned by KV VI. The general partner of KV VI is KVA VI. VK Services is the sole manager of KVA VI. Khosla is the managing member of VK Services. Each of Khosla, VK Services and KVA VI possesses power to direct the voting and disposition of the shares owned by KV VI, and each of KVA VI, VK Services and Khosla may be deemed to have indirect beneficial ownership of such shares.

    (3)

    The percentages set forth on the cover sheets are calculated based on 35,848,738 shares of Common Stock as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024.


    CUSIP No: 09077V100  

     

     1   

     NAMES OF REPORTING PERSONS

     

     Khosla Ventures Opportunity I, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,361,550 (2)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,361,550 (2)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,361,550 (2)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     3.8% (3)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    All of the shares are owned by KV Opp I. The general partner of KV Opp I is KVOA I. VK Services is the sole manager of KVOA I. Khosla is the managing member of VK Services. Each of Khosla, VK Services and KVOA I possesses power to direct the voting and disposition of the shares owned by KV Opp I, and each of Khosla, VK Services and KVOA I may be deemed to have indirect beneficial ownership of such shares.

    (3)

    The percentages set forth on the cover sheets are calculated based on 35,848,738 shares of Common Stock as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024.


    CUSIP No: 09077V100  

     

     1   

     NAMES OF REPORTING PERSONS

     

     Khosla Ventures Associates VI, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     437,152 (2)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     437,152 (2)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     437,152 (2)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     1.2% (3)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    All of the shares beneficially owned by KVA VI are comprised of Common Stock held by KV VI. The general partner of KV VI is KVA VI. VK Services is the sole manager of KVA VI. Khosla is the managing member of VK Services. Each of Khosla, VK Services and KVA VI possesses power to direct the voting and disposition of the shares owned by KV VI, and each of Khosla, VK Services and KVA VI may be deemed to have indirect beneficial ownership of such shares. KVA VI holds no shares of the Issuer directly.

    (3)

    The percentages set forth on the cover sheets are calculated based on 35,848,738 shares of Common Stock as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024.


    CUSIP No: 09077V100  

     

     1   

     NAMES OF REPORTING PERSONS

     

     Khosla Ventures Opportunity Associates I, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,361,550 (2)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,361,550 (2)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,361,550 (2)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     3.8% (3)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    All of the shares beneficially owned by KVOA I are comprised of Common Stock held by KV Opp I. The general partner of KV Opp I is KVOA I. VK Services is the sole manager of KVOA I. Khosla is the managing member of VK Services. Each of Khosla, VK Services and KVOA I possesses power to direct the voting and disposition of the shares owned by KV Opp I, and each of Khosla, VK Services and KVOA I may be deemed to have indirect beneficial ownership of such shares. KVOA I holds no shares of the Issuer directly.

    (3)

    The percentages set forth on the cover sheets are calculated based on 35,848,738 shares of Common Stock as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024.


    CUSIP No: 09077V100  

     

     1   

     NAMES OF REPORTING PERSONS

     

     VK Services, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,798,702 (2)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,798,702 (2)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,798,702 (2)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.0% (3)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    All of the shares beneficially owned by VK Services are comprised of shares of Common Stock held by KV VI and KV Opp I. The general partner of KV VI is KVA VI and the general partner of KV Opp I is KVOA I. VK Services is the sole manager of KVA VI and KVOA I. Khosla is the managing member of VK Services. Each of Khosla, VK Services and KVA VI possesses power to direct the voting and disposition of the shares owned by KV VI, and each of Khosla, VK Services and KVA VI may be deemed to have indirect beneficial ownership of such shares. Each of Khosla, VK Services and KVOA I possesses power to direct the voting and disposition of the shares owned by KV Opp I, and each of Khosla, VK Services and KVOA I may be deemed to have indirect beneficial ownership of such shares. VK Services holds no shares of the Issuer directly.

    (3)

    The percentages set forth on the cover sheets are calculated based on 35,848,738 shares of Common Stock as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024.


    CUSIP No: 09077V100  

     

     1   

     NAMES OF REPORTING PERSONS

     

     Vinod Khosla

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,798,702 (2)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,798,702 (2)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,798,702 (2)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.0% (3)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This statement on Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    All of the shares beneficially owned by Khosla are comprised of Common Stock held by KV VI and KV Opp I. The general partner of KV VI is KVA VI and the general partner of KV Opp I is KVOA I. VK Services is the sole manager of KVA VI, and KVOA I. Khosla is the managing member of VK Services. Each of Khosla, VK Services and KVA VI possesses power to direct the voting and disposition of the shares owned by KV VI, and each of Khosla, VK Services and KVA VI may be deemed to have indirect beneficial ownership of such shares. Each of Khosla, VK Services and KVOA I possesses power to direct the voting and disposition of the shares owned by KV Opp I, and each of Khosla, VK Services and KVOA I may be deemed to have indirect beneficial ownership of such shares. Khosla and VK Services hold no shares of the Issuer directly.

    (3)

    The percentages set forth on the cover sheets are calculated based on 35,848,738 shares of Common Stock as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024.


    Item 1(a).

    Name of Issuer:

    BioAge Labs, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    1445A South 50th Street

    Richmond, CA 94804

     

    Item 2(a).

    Name of Person(s) Filing:

    Khosla Ventures VI, LP (“KV VI”)

    Khosla Ventures Opportunity I, LP (“KV Opp I”)

    Khosla Ventures Associates VI, LLC (“KVA VI”)

    Khosla Ventures Opportunity Associates I, LLC (“KVOA I”)

    VK Services, LLC (“VK Services”)

    Vinod Khosla (“Khosla”)

     

    Item 2(b).

    Address of Principal Business Office:

    Khosla Ventures

    2128 Sand Hill Road

    Menlo Park, California 94025

     

    Item 2(c).

    Citizenship:

     

    KV VI    Delaware, United States of America
    KV Opp I    Delaware, United States of America
    KVA VI    Delaware, United States of America
    KVOA I    Delaware, United States of America
    VK Services    Delaware, United States of America
    Khosla    United States of America

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.00001 per share.

     

    Item 2(e).

    CUSIP Number:

    09077V100

     

    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

    Not applicable.

     

    Item 4(a).

    Amount Beneficially Owned:

     

    Item 4(b).

    Percent of Class:

     

    Item 4(c).

    Number of shares as to which such persons have:

    The following information with respect to the beneficial ownership of Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of November 14, 2024:


    Reporting Persons    Shares Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power (1)
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power (1)
         Beneficial
    Ownership(1)
         Percent
    of Class (1, 3)
     

    KV VI

         437,152        0        437,152        0        437,152        437,152        1.2 % 

    KV Opp 1

         1,361,550        0        1,361,550        0        1,361,550        1,361,550        3.8 % 

    KVA VI

         0        0        437,152        0        437,152        437,152        1.2 % 

    KVOA I

         0        0        1,361,550        0        1,361,550        1,361,550        3.8 % 

    VK Services

         0        0        1,798,702        0        1,798,702        1,798,702        5.0 % 

    Khosla

         0        0        1,798,702        0        1,798,702        1,798,702        5.0 % 

     

    (1)

    Represents the number of shares of Common Stock and the number of shares of Common Stock issuable upon exercise of options, warrants and other convertible securities that are exercisable within 60 days of the date of this statement on Schedule 13G currently beneficially owned by the Reporting Persons.

    (2)

    All of the shares beneficially owned by VK Services and Khosla are comprised of Common Stock held by KV VI and KV Opp I. The general partner of KV VI is KVA VI and the general partner of KV Opp I is KVOA I. VK Services is the sole manager of KVA VI and KVOA I. Khosla is the managing member of VK Services. Each of Khosla, VK Services and KVA VI possesses power to direct the voting and disposition of the shares owned by KV VI, and each of Khosla, VK Services and KVA VI may be deemed to have indirect beneficial ownership of such shares. Each of Khosla, VK Services and KVOA I possesses power to direct the voting and disposition of the shares owned by KV Opp I, and each of Khosla, VK Services and KVOA I may be deemed to have indirect beneficial ownership of such shares. Khosla and VK Services hold no shares of the Issuer directly.

    (3)

    The percentages set forth on the cover sheets are calculated based on 35,848,738 shares of Common Stock as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024.

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: ☐

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group:

    Not applicable.

     

    Item 10.

    Certifications:

    Not applicable.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

    KHOSLA VENTURES VI, LP
    By:   Khosla Ventures Associates VI, LLC, a Delaware limited liability company and general Partner of Khosla Ventures VI, LP
    By:  

    /s/ Vinod Khosla

      Vinod Khosla, Managing Member
    KHOSLA VENTURES OPPORTUNITY I, LP
    By:   Khosla Ventures Opportunity Associates I, LLC, a Delaware limited liability company and general Partner of Khosla Ventures Opportunity I, LP
    By:  

    /s/ Vinod Khosla

      Vinod Khosla, Managing Member
    KHOSLA VENTURES ASSOCIATES VI, LLC
    By:  

    /s/ Vinod Khosla

      Vinod Khosla, Managing Member
    KHOSLA VENTURES OPPORTUNITY ASSOCIATES I, LLC
    By:  

    /s/ Vinod Khosla

      Vinod Khosla, Manager
    VK SERVICES, LLC
    By:  

    /s/ Vinod Khosla

      Vinod Khosla, Manager

    /s/ Vinod Khosla

    Vinod Khosla


    Exhibit(s):     
    99.1:    Joint Filing Statement
    Get the next $BIOA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    10/21/2024$42.00Buy
    Jefferies
    10/21/2024$40.00Overweight
    Morgan Stanley
    More analyst ratings

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      10/3/24 7:19:49 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on BioAge Labs

      William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

      2/28/25 7:20:24 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

      12/10/24 7:54:08 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Jefferies with a new price target

      Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

      12/9/24 7:29:20 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/14/24 4:15:56 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/12/24 4:15:53 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioAge Labs Inc.

      SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

      10/4/24 8:21:35 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BIOA
    SEC Filings

    See more
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Chief Operating Officer Morgen Eric

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      2/25/25 4:28:11 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

      Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results. "The first quarter of 2025 was marke

      5/6/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

      Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended Decembe

      3/20/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioArctic receives Orphan Drug Designation for exidavnemab the US

      STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. Multiple System Atrophy (MSA) is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which

      3/17/25 1:49:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by BioAge Labs Inc.

      10-Q - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:40:22 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:35:09 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by BioAge Labs Inc.

      DEFA14A - BioAge Labs, Inc. (0001709941) (Filer)

      4/17/25 4:10:03 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care